Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$23.90+1.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ARQT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks ARQT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue strong growth of ZORYVE net product sales and raise full-year 2026 net product sales guidance to $525 million to $540 million.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $81.5 million in 2025-Q2 to $129.9 million in 2026-Q2 (+59% YoY). The Company raised 2026 full-year net product sales guidance from $480M–$495M to $525M–$540M, reflecting delivering strong growth and upward trajectory.
“Company raising 2026 full-year net product sales guidance to $525 million–$540 million”
“The Company continues to anticipate net product revenue of between $480 million and $495 million for the full year 2026.”
“the Company raised 2026 full year net product sales guidance to $480 million – $495 million.”
Advance regulatory approvals and clinical trials to expand ZORYVE indications including pediatric and new dermatological conditions.
Stated in 2 of last 2 quarters. Management reported FDA approval for ZORYVE cream 0.3% down to age 2 and FDA acceptance of sNDA for cream 0.05% for infants, with ongoing Phase 2 trials for vitiligo and hidradenitis suppurativa. The trajectory shows active regulatory and clinical progress consistent with stated priorities.
“Received approval to expand indication for ZORYVE cream 0.3% to children down to age 2; FDA accepted sNDA for cream 0.05% for infants”
Continue building and deploying targeted sales teams to support ZORYVE commercialization in dermatology, primary care, and pediatrics.
Stated in 2 of last 2 quarters. Management completed expansion of dermatology sales force and initiated a primary care and pediatric sales team build-out, including hiring leadership. This supports commercialization efforts and aligns with revenue growth, indicating delivering progress.
“Completed hiring of targeted sales team dedicated to primary care and pediatric healthcare providers”
Sustain positive cash flow from operating activities each quarter to support financial and operational discipline.
Stated in 2 of last 2 quarters. Operating cash flow improved from $2.2 million in 2026-Q1 to $12.6 million in 2026-Q2, reflecting positive cash generation. Management's focus on financial discipline is delivering with improving cash flow trajectory.
“Sustained positive cash flow, generating $12.6 million of cash flow from operating activities”
Appoint experienced executives to the Board to support strategic growth and pipeline development.
Newly stated in 2026-Q3 period. Management appointed Chris Peetz to the Board in July 2026 to leverage his biopharma leadership experience for strategic growth and pipeline development. This is a recent initiative with no prior quarters stating this priority.
Over the trailing year it converted 0.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Submitted sNDA for ZORYVE cream 0.05% to FDA to expand indication to infants ages 3 to 24 months”
“Completed expansion of dermatology sales force and initiated build-out of primary care and pediatrics-focused organization”
“Sustained positive cash flow, generating $2.2 million of positive cash flow from operating activities”